港股異動丨康哲藥業(0867.HK)大漲8%%破頂 市值達485億港元
格隆匯5月21日丨康哲藥業(0867.HK)午後漲幅擴大至8%,高見19.64港元創歷史新高價,暫成交1.26億港元,總市值達485億港元。為了進一步完善皮膚治療及高端醫美產品的戰略版圖,康哲藥業日前擬收購一家醫療美容聚焦超聲技術平台公司。通過本次交易,該公司將持有目標公司約64.81%的股權,目標公司將成為公司的非全資附屬公司,其業績及資產與負債將合併入集團的賬目內。集團認為皮膚治療及高端醫美市場前景廣闊,為此持續通過多元化投資。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.